National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

PAPERBACK
price:$45.75
add to cart

Rights & Permissions

topleft topright

A Risk-Characterization Framework for Decision-Making at the Food and Drug Administration (2011)
Board on Environmental Studies and Toxicology (BEST)

Citation Manager

. "3 Case Study of a Mitigation-Selection Decision." A Risk-Characterization Framework for Decision-Making at the Food and Drug Administration. Washington, DC: The National Academies Press, 2011.

Please select a format:

BibTeX EndNote RefMan


Page
65
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


A Risk-Characterization Framework for Decision-Making at the Food and Drug Administration

Keefer, D.L., and S.E. Bodily. 1983. Three-point approximations for continuous random variables. Manage. Sci. 29(5):595-609.

Kramarz, P., E.K. France, F. Destefano, S.B. Black, H. Shinefield, J.I. Ward, E.J. Chang, R.T. Chen, D. Shatin, J. Hill, T. Lieu, and J.M. Ogren. 2001. Population-based study of rotavirus vaccination and intussusception. Pediatr. Infect. Dis. J. 20(4):410-416.

Lieu, T.A., M. Kulldorff, R.L. Davis, E.M. Lewis, E. Weintraub, K. Yih, R. Yin, J.S. Brown, and R. Platt. 2007. Real-time vaccine safety surveillance for the early detection of adverse events. Med. Care 45(10 Suppl. 2):S89-S95.

Murphy, T.V., P.M. Gargiullo, M.S. Massoudi, D.B. Nelson, A.O. Jumaan, C.A. Okoro, L.R. Zanardi, S. Setia, E. Fair, C.W. LeBaron, B. Schwartz, M. Wharton, and J.R. Livengood. 2001. Intussusception among infants given an oral rotavirus vaccine. N. Engl. J. Med. 344(8):564-572.

Murphy, B.R., D.M. Morens, L. Simonsen, R.M. Chanock, J.R. La Montagne, and A.Z. Kapikian. 2003a. Reappraisal of the association of intussusception with the licensed live rotavirus vaccine challenged initial conclusions. J. Infect. Dis. 187(8):1301-1308.

Murphy, T.V., P.J. Smith, P.M. Gargiullo, and B. Schwartz. 2003b. The first rotavirus vaccine and intussusception: Epidemiological studies and policy decisions. J. Infect. Dis. 187(8):1309-1313.

Parashar, U.D., R.C. Holman, K.C. Cummings, N.W. Staggs, A.T. Curns, C.M. Zimmerman, S.F. Kaufman, J.E. Lewis, D.J. Vugia, K.E. Powell, and R.I. Glass. 2000. Trends in intussusception-associated hospitalizations and deaths among U.S. infants. Pediatrics. 10696:1413-1421.

Perez-Schael, I., M.J. Guntinas, M. Perez, V. Pagone, A.M. Rojas, R. Gonzalez, W. Cunto, Y. Hoshino, and A.Z. Kapikian. 1997. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. N. Engl. J. Med. 337(17):1181-1187.

Rennels, M.B., R.I. Glass, P.H. Dennehy, D.I. Bernstein, M.E. Pichichero, E.T. Zito, M.E. Mack, B.L. Davidson, and A.Z. Kapikian. 1996. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines—report of the National Multicenter Trial. Pediatrics 97(1):7-13.

Rennels, M.B., U.D. Parashar, R.C. Holman, C.T. Le, H.G. Chang, and R.I. Glass. 1998. Lack of an apparent association between intussusception and wild or vaccine rotavirus infection. Pediatr. Infect. Dis. J. 17(10):924-925.

Santosham, M., L.H. Moulton, R. Reid, J. Croll, R. Weatherholt, R. Ward, J. Forro, E. Zito, M. Mack, G. Brenneman, and B.L. Davidson. 1997. Efficacy and safety of high-dose rhesus-human reassortant rotavirus vaccine in Native American populations. J. Pediatr. 131(4):632-638.

Tucker, A.W., A.C. Haddix, J.S. Bresee, R.C. Holman, U.D. Parashar, and R.I. Glass. 1998. Cost-effectiveness analysis of a rotavirus immunization program for the United States. JAMA. 279(17):1371-1376.

Page
65